RECRUITING

Behavioral Intervention for Youth to Promote Vaping Cessation

Conditions

Vaping Vaping Teens Nicotine Dependence Nicotine Depedence Vaping Cessation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will test the hypothesis that the QuitVaping (QV) intervention and additional texting support will improve nicotine abstinence rates in adolescents as compared to Enhanced Usual Care (EUC: education about nicotine, vaping and addiction, advice to quit vaping, referral to TIQ texting support). Approximately 400 adolescents will be randomly assigned to one of two arms (1) QuitVaping intervention plus texting support to quit vaping and (2) EUC only.

Official Title

Behavioral Intervention for Youth to Promote Vaping Cessation

Quick Facts

Study Start:2025-06-18

Study Completion:2028-09-27

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06765291

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:14 Years to 18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* Age 14-18 inclusive * Self-report of at least weekly nicotine vaping for the prior ≥3 months and semiquantitative saliva screening for cotinine positive for recent nicotine use * Self-report of no regular combusted tobacco use (5 consecutive days of smoked tobacco use) in the 2 months prior to enrollment and exhaled CO \<10 ppm * Report willingness to try to quit vaping in the next 30 days * Able to understand study procedures and read and write in English or Spanish * Have a parent or legal guardian who is able and willing to provide written informed consent (if under age 18) * Competent and willing to provide written informed consent (if age 18) or assent (if under 18)	* Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion) * Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study * Unwilling to provide saliva or urine samples * Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol

Inclusion Criteria

Exclusion Criteria

* Age 14-18 inclusive
* Self-report of at least weekly nicotine vaping for the prior ≥3 months and semiquantitative saliva screening for cotinine positive for recent nicotine use
* Self-report of no regular combusted tobacco use (5 consecutive days of smoked tobacco use) in the 2 months prior to enrollment and exhaled CO \<10 ppm
* Report willingness to try to quit vaping in the next 30 days
* Able to understand study procedures and read and write in English or Spanish
* Have a parent or legal guardian who is able and willing to provide written informed consent (if under age 18)
* Competent and willing to provide written informed consent (if age 18) or assent (if under 18)

* Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion)
* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study
* Unwilling to provide saliva or urine samples
* Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol

Contacts and Locations

Study Contact

A. Eden Evins, MD, MPH

CONTACT

617-643-4679

aeevins@mgh.harvard.edu

Julia Jashinski, MSW

CONTACT

617-643-1984

jjashinski@mgh.harvard.edu

Principal Investigator

A. Eden Evins, MD, MPH

PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Randi M. Schuster, PhD

PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Study Locations (Sites)

Massachusetts General Hospital, Center for Addiction Medicine, 101 Merrimac Street, Suite 320, Boston, MA 02114

Boston, Massachusetts, 02114

United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

A. Eden Evins, MD, MPH, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital
Randi M. Schuster, PhD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-18

Study Completion Date2028-09-27

Study Record Updates

Study Start Date2025-06-18

Study Completion Date2028-09-27

Terms related to this study

Keywords Provided by Researchers

Vaping
Nicotine Depedence
Vaping Cessation

Additional Relevant MeSH Terms

Vaping
Vaping Teens
Nicotine Dependence